271 related articles for article (PubMed ID: 20049473)
1. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
Marsh EA; Hirst CL; Llewelyn JG; Cossburn MD; Reilly MM; Krishnan A; Doran M; Ryan AM; Coles AJ; Jones JL; Robertson NP
J Neurol; 2010 Jun; 257(6):913-9. PubMed ID: 20049473
[TBL] [Abstract][Full Text] [Related]
2. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
3. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
4. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
Hirst C; Raasch S; Llewelyn G; Robertson N
J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):800-2. PubMed ID: 16705208
[No Abstract] [Full Text] [Related]
5. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
6. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
9. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Cavaletti G; Giannini F; Sabatelli M; Beghi E;
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):729-34. PubMed ID: 25246645
[TBL] [Abstract][Full Text] [Related]
10. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.
Vina ER; Fang AJ; Wallace DJ; Weisman MH
Semin Arthritis Rheum; 2005 Dec; 35(3):175-84. PubMed ID: 16325658
[TBL] [Abstract][Full Text] [Related]
11. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
12. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
Melzer N; Meuth SG
Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
[TBL] [Abstract][Full Text] [Related]
14. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy.
Opala AR; Kennedy K; Baker SK
Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
[TBL] [Abstract][Full Text] [Related]
16. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
17. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
19. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
20. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Cocito D; Paolasso I; Antonini G; Benedetti L; Briani C; Comi C; Fazio R; Jann S; Matà S; Mazzeo A; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2010 Feb; 17(2):289-94. PubMed ID: 19863650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
